Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Bank of America Securities analyst Sachin Jain maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com ...

Novo Nordisk AS (OCSE:NOVO B) is set to release its Q4 2024 earnings on Feb 5, 2025. The consensus estimate for Q4 2024 revenue is $79.26 billion, and the earnings are expected to come in at $5.78 per ...

It remains committed to hitting its 2025 target this year ... valuation last year. While Novo Nordisk increased sales and profits last year, the company’s share price took a battering in the ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

Novo Nordisk’s CEO toasted the company’s record ... is comprised of four equally weighted target areas, spanning commercial and social goals in addition to a measure of individual performance ...